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Corticosteroid injection (CSI) is a mainstay of 
treatment for many musculoskeletal condi-
tions. We are concerned with the apparent 
wholesale withdrawal of CSI as a legiti-
mate treatment option for patients who are 
sufering from hand, wrist and other muscu-
loskeletal conditions during the COVID-19 
pandemic. As patients sufer and routine 
operating (based on the COVID-19 triage 
system) seems months away, surgical alterna-
tives are unlikely to be available, and indeed 
it is good practice to consider an injection 
before committing to surgery (which is often 
a requirement prior to funding in the NHS). 
For hand- related conditions such as nerve 
compression, base of thumb arthritis and 
several tendon- related pathologies (trigger 
digit and de Quervain’s), there are few reli-
able alternatives.
The onset of the current COVID-19 viral 
outbreak prompted appropriate reviews 
of clinical services and practice to prevent 
patients from attending healthcare institu-
tions, in particular those with underlying 
conditions that would render them vulner-
able to severe viral infection, in order to mini-
mize the spread of the COVID-19 virus and 
to allow hospitals and healthcare services 
to realign their focus in order to prevent the 
available resources from being overwhelmed. 
Given the potential immunosuppressive 
efects of CSI, various national professional 
bodies issued guidance surrounding the 
safety and appropriateness of its use as a part 
of this national efort, discouraging clinicians 
from ofering CSI as a treatment modality.1-4 
The rationale underpinning the published 
guidance appears to have been inluenced 
by observations which were attributable to 
the administration of systemic corticoste-
roids during previous Middle east Respira-
tory Syndrome, Severe Acute Respiratory 
Syndrome and inluenza epidemics.1-4 While 
close reading of the published guidelines 
shows they have recommended a cautious 
risk- beneit analysis on a case- by- case basis, 
in practice the guidance has been widely 
interpreted as representing an instruction 
to cease CSI to treat most musculoskeletal 
conditions.
Given the true impact of CSI on a patient’s 
immunity during the outbreak remains 
poorly understood, as patients return to 
seeking treatments for their painful and 
debilitating musculoskeletal conditions, it is 
increasingly important to determine which 
treatments can and should be ofered to 
them, balancing the risks of CSI against the 
established eicacy of the injections, and the 
relatively unavailable surgical alternatives. 
We have therefore critically appraised the 
literature and evidence that the British Pain 
Society, British Society of Skeletal Radiology 
(BSSR), and other societies have used when 
generating their respective guidance in 
order to inform clinicians when counsel-
ling patients who present to them for treat-
ments now that the initial peak of COVID-19 
epidemic appears to be passing.
The cited papers describe safety concerns 
related to injections and changes to recipi-
ents’ systemic physiology resulting from 
the exogenous steroid. In a paper looking 
at the efects of epidural CSI, Friedly et al5 
observed that adrenal suppression occurred 
following injection with no relationship 
to other patient characteristics, although 
reported that only 1/149 sufered an adverse 
event that could have potentially related to 
immunosuppression (pneumonia) despite 
the relatively high steroid doses being 
used (up to 120 mg methylprednisolone). 
A review by Youssef et al6 considering the 
infection risk and safety of corticosteroid 
use in patients with rheumatic conditions 
found that for systemic infections, evidence 
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from randomized controlled trials (RCTs) showed ‘no 
signiicant increased risk of infection was noted in the 
corticosteroid arms in most of the trials’, although their 
review of observational studies found corticosteroid 
use conferred a dose- related increased risk of infection 
and the authors recommended an analysis of the risk- 
beneit ratio; patients with rheumatic conditions are a 
group whose underlying condition is known to confer 
approximately double the population baseline risk of 
developing infections.7 As the observed increased risk 
in observational studies was dose- dependent, it is 
important to distinguish between the very small doses 
used in most musculoskeletal CSI compared to the 
doses described in the quoted literature.
The Lancet papers of both Huang8 (an observational 
case series from Wuhan) and Russell9 (a commentary 
published in the same edition of The Lancet) both 
relate to therapeutic use of systemic corticosteroid in 
the treatment of patients hospitalized with COVID-19 
infection, and so are not of direct relevance to single- 
dose peripheral CSI in asymptomatic patients for the 
management of musculoskeletal pathology; the papers 
recommended against systemic use of corticosteroids in 
the treatment of established COVID-19 infection. Other 
authors however have systematically reviewed the 
available evidence regarding treatment with immune- 
supressive and stimulating drugs and COVID-19 infec-
tion and concluded that despite the interim World 
Heath Organization (WHO) advice against therapeutic 
use of corticosteroids in the treatment of COVID-19 
infections, there was evidence that “low- dose pred-
nisolone (and tacrolimus) therapy may have beneicial 
impacts on the course of SARS- CoV-2”, although noting 
that this observation was not speciic for COVID-19, 
and the observation required further validation.10 In 
any event, the systemic efect of peripheral CSI upon 
endogenous cortisol pathways is relatively short- lived; 
Habib11 found the systemic efect of CSI on endogenous 
cortisol appears to be maximal after 48 hours and to 
last for one to four weeks.
The potential for CSI increasing susceptibility to viral 
infection was drawn from the 2018 Sytsma et al12 study, 
which considered the potential inluence of CSI on the 
subsequent risk of contracting inluenza; the retrospec-
tive study found on multivariate analysis that CSI was 
the most important predictive factor for contracting 
inluenza, with overall rates of observed inluenza infec-
tion over the ive year period considered of 1.08% in 
the 43,236 vaccinated control patients, 1.64% in 15,018 
vaccinated patients who also had at least one CSI, and 
1.70% in 4,804 unvaccinated patients who received 
at least one CSI; this represents an absolute increase in 
annual infection risk of only around one in 1,000. The 
mean dose- equivalent of methylprednisolone adminis-
tered with each CSI was 65.9 mg (over x1.5 the standard 
dose administered with single site injections in the hand 
and upper limb). unfortunately, the paper did not report 
the timeline of events (CSI- immunization- infection), 
which in light of the time course of adrenal suppression 
noted above would have been important to know when 
interpreting the relevance of the observed diferences.
British clinicians are practicing in an environment 
where they feel that they would be subject to reproach in 
the event that they should consider CSI for their patients. 
Other developed countries have not proceeded down 
the road of strongly recommending against CSI in the 
management of patients with musculoskeletal prob-
lems despite the pandemic; the only national guidance 
issued in the uSA was a joint statement from the Amer-
ican Society of Regional Anaesthesia and Pain Medicine 
and the european Society of Regional Anaesthesia & 
Pain Therapy,13 which noted the implications of CSI in 
terms of inluenza risk and immune suppression, and 
advocated that clinicians should “consider evaluating 
risks/beneits of steroid injections and use a decreased 
dose, especially in high- risk patient populations”. The 
Australasian Musculoskeletal Imaging Group (AMSIG) 
issued a response to the recommendations from the 
BSSR in a bulletin headlined “AMSIG recommends that 
members continue to perform image- guided corti-
costeroid injections during the COVID-19 pandemic 
where they are clinically indicated following informed 
consent” and noting that the BSSR statement had not 
in fact advocated complete cessation of CSI despite 
the C19 pandemic.14 Of additional note, the Allergic 
Rhinitis and its Impact on Asthma- european Academy 
of Allergic and Clinical Immunology (ARIA- eAACI) joint 
statement has recommended that intra- nasal cortico-
steroid use should not be stopped even in patients with 
C19, stating that suppression of the immune system 
had not been proven and that sneezing could dissemi-
nate the virus,15 despite the evidence of a small (4.2%) 
risk of cortisol suppression from intranasal steroid cited 
in the systematic review of Broersen et al.16
On irst review, the current uk guidance has been 
interpreted as being of direct relevance to the present 
COVID-19 pandemic, and in light of the wording of the 
documents (indicating that risks apply to asymptomatic 
individuals who may be incubating COVID-19 (i.e. poten-
tially all people, given the high community prevalence 
of COVID-19)4 as representing an absolute or at least a 
strong contraindication to administration of even low 
dose CSI. However, our review of the various documents 
show that they do not in fact advocate the complete 
cessation of CSI, but that prior to proceeding with CSI, 
clinicians should think about and discuss the potential 
risks and beneits of the CSI to their patients. In the NHS 
england document of 25 March they recommend ‘only 
consider steroids if patient has high levels of pain and 
disability, has failed irst- line measures and continuation 
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of those symptoms will have a signiicant negative efect 
on their health and wellbeing’;3 we consider this advice 
relects a position where, with appropriate caution and 
thought, CSI can continue to be ofered to patients.
When faced with uncertainty, it is understandable to 
remain circumspect. While the guidelines have not advo-
cated an embargo on CSI, it appears that many practi-
tioners and providers are reluctant to consider CSI as a 
treatment option during this pandemic. Such approach 
would deny patients a treatment that could alleviate pain 
and improve quality of life. In the current climate where 
the timing of reinstatement of elective surgery remains 
indeterminate, judicious use of CSI for many patients 
would delay, if not remove, their need for surgery.
While considering and exploring non- interventional 
treatments and, in the event that none are acceptable or 
efective, minimizing the total dosage of corticosteroid 
administered in the event of injections being requested 
seems sensible, nevertheless removing CSI as a legiti-
mate treatment option does not seem to be a measured 
or responsible medium- to- long term choice for the good 
of a sizable cohort of patients. Musculoskeletal condi-
tions represented a substantial primary care burden, 
prompting approximately one in four attendances,17,18 
only a proportion of which reach secondary care, given 
the prevalence of carpal tunnel syndrome (7% to 16%),19 
trigger inger (~ 3%)20 and thumb- base arthritis (1.4% 
overall, > 5% in women aged 70 to 74 years)21 to mention 
only a few of the hand conditions commonly treated by 
CSI, which is a treatment widely used in many other 
musculoskeletal conditions. Minimally- invasive treat-
ments, such as CSI, have long played an important role 
in addressing patients’ symptoms without the need to 
revert to hospital attendances, a role that is particularly 
important in the current viral climate to stop potentially 
vulnerable patients from needing to attend hospitals, or 
to need to be considered for surgery.
A reassessment of the existing guidance and a balanced 
consideration of the evidence, avoiding any unintended 
inhibiting efects of interpretation is required. We think it 
is important that practice accurately relects the content of 
the current guidelines on the use of CSI. Where a patient 
has signiicant disease activity and there are no efective 
alternatives, CSI should be considered following a shared 
risk assessment with the patient as part of ‘Montgomery 
guided’ consent process.
With careful shared decision- making, recognizing the 
potential but, in all probability, very low risks of CSI in the 
setting of COVID-19, and after appropriate patient selec-
tion and counselling, we feel continued use of CSI in low 
doses remains an appropriate treatment option for many 
patients.
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